We would like to thank you sincerely for your trust and cooperation throughout the year.
2020 was a year full of unfamiliar challenges. Living through a pandemic showed us here at Transo-Pharm that business relations not only consists of successful projects and “numbers”. It´s the emotional part that´s missing when fairs and in-person meetings are canceled. We hope that we can all meet again soon.
The entire Transo-Pharm team wishes you a wonderful Christmas Season and a Happy New Year.
Alkaloids produces two grades on a commercial basis: non-micronized and micronized material.
The existing CEP has been amended and now includes the micronization step, hence the current version No. R1-CEP 2010-298-Rev 01 covers now both grades, micronized and non-micronized material. The revision also includes editorial updates and notifications. We believe this new version represents a significant improvement over the previous version and will support our customers with their drug product registrations.
The micronization step is done in-house. Importantly, the micronized material from Alkaloids does not require any special cooling during transportation or storage.
Enantiomeric purity – and the associated advantages of Transo-Pharm’s Epinephrine (synonym = Adrenaline)
Enantiomeric purity in chiral molecules – such as Transo-Pharm’ s Epinephrine Base and Bitartrate – have been in the focus of the health authorities for some time now. Transo-Pharm is well prepared to fully satisfy the more stringent requirements with their state-of-the-art stereo-selective manufacturing process. Transo-Pharm is therefore in the position to achieve an Enantiomeric Excess (ee) of 99% in commercial production for several years now. This is a significant contribution to ensure patient safety.
Please find the full article below. Learn more about the science behind this topic.